Maria M. Xu

Maria M. Xu

Auto-generated profile, based on publicly available information

Maria M. Xu

Department of Immunology, University of Connecticut School of Medicine, Farmington (A.M., M.M.X., E.R.J., B.Z., A.T.V.).

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2015 in Nature Materials
Verified
Journal Article
Open access
PDF file
NHNathaniel Huebsch
Nathaniel Huebsch
ELEvi Lippens
Evi Lippens
KLKangwon Lee
Kangwon Lee
MMManav Mehta
Manav Mehta
SKSandeep T. Koshy
Sandeep T. Koshy
DMDavid J. Mooney
David J. Mooney
The effectiveness of stem cell therapies has been hampered by cell death and limited control over fate. These problems can be partially circumvented by using macroporous biomaterials that improve the survival of transplanted stem cells and provide molecular cues to direct cell phenotype. Stem cell behaviour can also be controlled in vitro by manipulating the elasticity of both porous and non-porous materials, yet translation to therapeutic processes in vivo remains elusive. Here, by developing injectable, void-forming hydrogels that decouple pore formation from elasticity, we show that mesenchymal stem cell (MSC) osteogenesis in vitro, and cell deployment in vitro and in vivo, can be controlled by modifying, respectively, the hydrogel’s elastic modulus or its chemistry. When the hydrogels were used to transplant MSCs, the hydrogel’s elasticity regulated bone regeneration, with optimal bone formation at 60 kPa. Our findings show that biophysical cues can be harnessed to direct therapeutic stem cell behaviours in situ.

1 January 2018 in Translational Research
Verified
Journal Article
Closed access
CLChuan Li
Chuan Li
MXMaria M. Xu
Maria M. Xu
KWKepeng Wang
Kepeng Wang
AAAdam J. Adler
Adam J. Adler
AVAnthony T. Vella
Anthony T. Vella
BZBeiyan Zhou
Beiyan Zhou

1 March 2014 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
BGBrian C. Geyer
Brian C. Geyer
MXMaria Xu
Maria Xu
CKChristopher Kabrhel
Christopher Kabrhel

1 June 2019 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
PDF file
MXMaria M. Xu
Maria M. Xu
AMAntoine Ménoret
Antoine Ménoret
SNSarah-Anne E. Nicholas
Sarah-Anne E. Nicholas
SGSebastian Guenther
Sebastian Guenther
ESEric J. Sundberg
Eric J. Sundberg
AVAnthony T. Vella
Anthony T. Vella
Effector CD8 T cells infiltrate atherosclerotic lesions and are correlated with cardiovascular events, but the mechanisms regulating their recruitment and retention are not well understood. CD137 (4–1BB) is a costimulatory receptor induced on immune cells and expressed at sites of human atherosclerotic plaque. Genetic variants associated with decreased CD137 expression correlate with carotid-intimal thickness and its deficiency in animal models attenuates atherosclerosis. These effects have been attributed in part to endothelial responses to low and disturbed flow (LDF), but CD137 also generates robust effector CD8 T cells as a costimulatory signal. Thus, we asked whether CD8 T cell-specific CD137 stimulation contributes to their infiltration, retention, and IFNγ production in early atherogenesis. We tested this through adoptive transfer of CD8 T cells into recipient C57BL/6J mice that were then antigen primed and CD137 costimulated. We analyzed atherogenic LDF vessels in normolipidemic and PCSK9-mediated hyperlipidemic models and utilized a digestion protocol that allowed for lesional T-cell characterization via flow cytometry and in vitro stimulation. We found that CD137 activation, specifically of effector CD8 T cells, triggers their intimal infiltration into LDF vessels and promotes a persistent innate-like proinflammatory program. Residence of CD137+ effector CD8 T cells further promoted infiltration of endogenous CD8 T cells with IFNγ-producing potential, whereas CD137-deficient CD8 T cells exhibited impaired vessel infiltration, minimal IFNγ production, and reduced infiltration of endogenous CD8 T cells. Our studies thus provide novel insight into how CD137 costimulation of effector T cells, independent of plaque-antigen recognition, instigates their retention and promotes innate-like responses from immune infiltrates within atherogenic foci. NEW & NOTEWORTHY Our studies identify CD137 costimulation as a stimulus for effector CD8 T-cell infiltration and persistence within atherogenic foci, regardless of atherosclerotic-antigen recognition. These costimulated effector cells, which are generated in pathological states such as viral infection and autoimmunity, have innate-like proinflammatory programs in circulation and within the atherosclerotic microenvironment, providing mechanistic context for clinical correlations of cardiovascular morbidity with increased CD8 T-cell infiltration and markers of activation in the absence of established antigen specificity. Listen to this article's corresponding podcast at https://ajpheart.podbean.com/e/effector-cd8-t-cells-seed-atherogenic-foci/ .

1 June 2019 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
MXMaria M. Xu
Maria M. Xu
PMPatrick A. Murphy
Patrick A. Murphy
AVAnthony T. Vella
Anthony T. Vella
Atherosclerosis is a chronic inflammatory pathology that precipitates substantial morbidity and mortality. Although initiated by physiological patterns of low and disturbed flow that differentially prime endothelial cells at sites of vessel branch points and curvature, the chronic, smoldering inflammation of atherosclerosis is accelerated by comorbidities involving inappropriate activation of the adaptive immune system, such as autoimmunity. The innate contributions to atherosclerosis, especially in the transition of monocyte to lipid-laden macrophage, are well established, but the mechanisms underpinning the infiltration, persistence, and effector dynamics of CD8 T cells in particular are not well understood. Adaptive immunity is centered on a classical cascade of antigen recognition and activation, costimulation, and effector cytokine secretion upon recall of antigen. However, chronic inflammation can generate alternative cues that supplant this behavior pattern and promote the retention and activation of peripherally activated T cells. Furthermore, the atherogenic foci that activated immune cell infiltrate are unique lipid-laden environments that offer a diverse array of stimuli, including those of survival, antigen hyporesponsiveness, and inflammatory cytokine expression. This review will focus on how known cardiovascular comorbidities may be influencing CD8 T-cell activation and how, once infiltrated within atherogenic foci, these T cells face a multitude of cues that skew the classical cascade of T-cell behavior, highlighting alternative modes of activation that may help contextualize associations of autoimmunity, viral infection, and immunotherapy with cardiovascular morbidity.

1 June 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
SNSarah-Anne E. Nicholas
Sarah-Anne E. Nicholas
SHStephen B. Helming
Stephen B. Helming
AMAntoine Ménoret
Antoine Ménoret
CPChristopher L. Pathoulas
Christopher L. Pathoulas
MXMaria M. Xu
Maria M. Xu
PMPatrick A. Murphy
Patrick A. Murphy
BACKGROUND: Atherosclerotic plaques form through lipid and immune cell accumulation beneath the arterial endothelium. CD8 (cluster of differentiation 8) T cells are abundant in lesions, and their activation correlates with cardiovascular disease severity. Although endothelial cells recruit CD8 T cells to low and disturbed flow regions, whether they regulate CD8 activation and persistence is unknown. These interactions may be mediated by posttranscriptional control of mRNA translation. METHODS: We used ribosomal profiling in Cdh5(PAC ); RiboTRAP mice to assess posttranscriptional regulation in atherosclerotic endothelium in a partial carotid ligation model. We then used CreERT2; Elavl ff; RiboTRAP (endothelial cell–knockout) mice to examine the impact of endothelial Elavl1 (ELAV-like RNA-binding protein 1) on gene expression programs and immune cell activity. RESULTS: Elavl1 motifs were enriched near alternative splicing events, and within 5′ untranslated regions of transcripts with altered ribosomal association in atherosclerosis. Elavl1 suppressed gene expression programs occurring in atherogenic endothelium, as deletion enhanced these responses and reduced CD8 T-cell accumulation (≈70%) at plaques without affecting recruitment, consistent with impaired persistence. In vitro, Elavl1-deficient endothelial cells suppressed antigen-dependent CD8 T-cell persistence, even in the presence of wild-type myeloid antigen-presenting cells and cognate antigen. CONCLUSIONS: Endothelial Elavl1 suppression enables endothelial cells to function as local immune checkpoint–like regulators of CD8 T-cell persistence in atherosclerosis. Thus, endothelial Elavl1 is a key regulator of adaptive immunity.